Thalassemia

Documentary fails to reflect role of drug for patients with rare blood disease

Published in Blood Weekly, May 29th, 2003

True Vision's documentary, Dying for Drugs, which aired on April 27, misrepresented many elements of the development of Ferriprox (deferiprone), a drug developed by Apotex, Inc., for the treatment of a life-threatening conditionchronic iron overload, a condition prevalent in thalassemia patients.

Prior to deferiprone, there was only one drug for the treatment of patients with iron overload, and it required daily injections of 8-12 hours, for the rest of the patient's life. In search for an alternative medicine, specialists in the U.K. and around the world, devoted up to 15 years of their lives to evaluate the safety and efficacy of deferiprone in thousands of patients....

Want to see the full article?

Purchase this article for only $3.00

We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.

Welcome to NewsRx!

Learn more about a six-week, no-risk free trial of Blood Weekly

Source: Blood Weekly (2003-05-29)

NewsRx is Social

Top Medical Newsletters

Awards

Best Health/Healthcare Content, 2012
Best Health/Healthcare Content, 2011
Best e-Business Site, 2010
Best e-Business Site, 2009
Best e-Business Site, 2008
Best e-Business Site, 2007
Best e-Business Site, 2006
Best Healthcare Content, 2005
Best Overall Internet Site, 2005
Best Interactive Site, 2005

Facts & Stats

NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.

Google 2010 PageRank: #2 Among Top Health News and Media Publications
Google 2010 PageRank: #2 Among Top Science Publications in Biology/Physiology
Google 2010 PageRank: #2 Among Top News and Media for the Business of Pharmaceuticals
Amazon's Alexa 2010 PageRank: #2 News and Media Site for the Pharmaceutical Industry